Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery

PHASE4TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

February 28, 2013

Conditions
AnemiaOrthopedic SurgeryHigh Risk of Blood Loss
Interventions
DRUG

Ferinject 50 mg/ml

iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes

DRUG

NaCl 0.9%

iv administration of max. 50 ml in 30 minutes

Trial Locations (2)

Unknown

Charité Universitätsmedizin Berlin, Berlin

D-48149

University Hospital Muenster, Münster

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Vifor Pharma

INDUSTRY

lead

University Hospital Muenster

OTHER